Horizon Therapeutics is a pharmaceutical company that focuses on developing and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. Founded in 2008 and headquartered in Dublin, Ireland, Horizon Therapeutics has rapidly established itself as a leader in the biopharmaceutical industry, with a diverse portfolio of innovative therapies that address unmet medical needs. Horizon Therapeutics is committed to improving the lives of patients by providing access to transformative treatments that offer hope and relief from debilitating conditions.
Horizon Therapeutics is driven by a patient-centric approach to drug development and commercialization. The company’s mission is to deliver breakthrough therapies that make a meaningful difference in patients’ lives, empowering them to live fuller, healthier, and more fulfilling lives. Horizon Therapeutics prioritizes patient advocacy and engagement, working closely with patient communities, advocacy groups, and healthcare providers to better understand the needs and challenges of patients living with rare and severe diseases. By listening to patients and incorporating their perspectives into every aspect of its business, Horizon Therapeutics ensures that its therapies address the most pressing needs and deliver the greatest impact.
Founded in 2008, Horizon Therapeutics is a global biopharmaceutical company dedicated to delivering medicines that address unmet treatment needs for rare and rheumatic diseases. Horizon Therapeutics is committed to researching, developing, and commercializing innovative treatments that improve the lives of patients and their families. With a focus on patient-centered care and a dedication to scientific excellence, Horizon Therapeutics is transforming the treatment landscape for a wide range of debilitating conditions. Through its robust pipeline of investigational therapies and its ongoing commitment to research and development, Horizon Therapeutics continues to advance the field of medicine and bring hope to patients around the world.
Horizon Therapeutics’ commitment to innovation and excellence is evident in its diverse portfolio of therapies targeting rare, autoimmune, and severe inflammatory diseases. The company’s research and development efforts are guided by a deep understanding of the underlying mechanisms of disease and a relentless pursuit of new treatment options. Horizon Therapeutics leverages cutting-edge technologies, scientific expertise, and strategic collaborations to identify promising drug candidates and advance them through preclinical and clinical development.
One of Horizon Therapeutics’ flagship products is Krystexxa (pegloticase), an enzyme therapy approved for the treatment of chronic gout refractory to conventional therapy. Krystexxa is a biologic therapy that works by converting uric acid into a soluble form that can be easily excreted by the kidneys, thereby reducing uric acid levels in the blood and joints. By addressing the underlying cause of chronic gout, Krystexxa provides significant relief from pain, inflammation, and joint damage, allowing patients to regain mobility and improve their quality of life.
In addition to Krystexxa, Horizon Therapeutics has a robust pipeline of investigational therapies targeting a variety of rare and severe diseases. One such therapy is teprotumumab, a fully human monoclonal antibody being developed for the treatment of thyroid eye disease (TED), a rare autoimmune condition characterized by inflammation and swelling of the tissues behind the eyes. Teprotumumab has shown promising results in clinical trials, demonstrating significant improvement in proptosis (bulging of the eyes) and other disease symptoms compared to placebo. If approved, teprotumumab has the potential to become a first-in-class treatment for TED and provide much-needed relief for patients suffering from this debilitating condition.
Another promising therapy in Horizon Therapeutics’ pipeline is KRYSTAL-1 (KRYSTEXXA Safety and Efficacy Study in Patients with Advanced Chronic Kidney Disease), a phase 3 clinical trial evaluating the safety and efficacy of Krystexxa in patients with chronic kidney disease (CKD) and uncontrolled gout. CKD is a common comorbidity in patients with gout and presents unique challenges in the management of the disease. KRYSTAL-1 aims to assess the benefits and risks of Krystexxa treatment in this patient population and provide valuable insights into the optimal management of gout in CKD.
In addition to its focus on drug development, Horizon Therapeutics is committed to expanding access to its therapies and improving healthcare outcomes for patients worldwide. The company collaborates with healthcare providers, payers, and patient advocacy organizations to raise awareness of rare and severe diseases, reduce barriers to treatment access, and support patients throughout their treatment journey. Horizon Therapeutics’ patient support programs offer financial assistance, medication access, and educational resources to help patients navigate the complexities of their condition and achieve better health outcomes.
Furthermore, Horizon Therapeutics is dedicated to corporate social responsibility and environmental sustainability. The company prioritizes ethical business practices, transparency, and accountability in all aspects of its operations. Horizon Therapeutics is committed to minimizing its environmental footprint through sustainable practices and initiatives aimed at reducing waste, conserving resources, and promoting eco-friendly alternatives. By integrating sustainability into its business strategy, Horizon Therapeutics demonstrates its commitment to making a positive impact on society and the environment.
Horizon Therapeutics is a leading biopharmaceutical company dedicated to improving the lives of patients with rare, autoimmune, and severe inflammatory diseases. With a patient-centric approach to drug development, a robust pipeline of innovative therapies, and a commitment to access and affordability, Horizon Therapeutics is at the forefront of advancing healthcare and transforming the treatment landscape for underserved patient populations. As the company continues to grow and innovate, it remains steadfast in its mission to deliver hope and healing to patients in need, one breakthrough therapy at a time.
Horizon Therapeutics, a global biopharmaceutical company headquartered in Dublin, Ireland, is dedicated to delivering medicines that address unmet treatment needs for rare and rheumatic diseases. Since its founding in 2008, Horizon Therapeutics has been committed to researching, developing, and commercializing innovative treatments that improve the lives of patients and their families. The company’s mission is to provide transformative therapies that offer hope and relief from debilitating conditions, empowering patients to live fuller, healthier, and more fulfilling lives.
Horizon Therapeutics’ patient-centric approach is evident in its deep engagement with patient communities, advocacy groups, and healthcare providers. By listening to patients and incorporating their perspectives into every aspect of its business, Horizon Therapeutics ensures that its therapies address the most pressing needs and deliver the greatest impact. The company collaborates closely with patients and caregivers to understand their experiences, challenges, and aspirations, guiding its research and development efforts to focus on areas of high unmet medical need.
One of Horizon Therapeutics’ flagship products is Krystexxa (pegloticase), an enzyme therapy approved for the treatment of chronic gout refractory to conventional therapy. Chronic gout is a painful and debilitating condition caused by the buildup of uric acid crystals in the joints, leading to severe pain, inflammation, and joint damage. Krystexxa works by converting uric acid into a soluble form that can be easily excreted by the kidneys, thereby reducing uric acid levels in the blood and joints. By addressing the underlying cause of chronic gout, Krystexxa provides significant relief from pain and inflammation, allowing patients to regain mobility and improve their quality of life.
In addition to Krystexxa, Horizon Therapeutics has a robust pipeline of investigational therapies targeting a variety of rare and severe diseases. One such therapy is teprotumumab, a fully human monoclonal antibody being developed for the treatment of thyroid eye disease (TED), a rare autoimmune condition characterized by inflammation and swelling of the tissues behind the eyes. Teprotumumab has shown promising results in clinical trials, demonstrating significant improvement in proptosis (bulging of the eyes) and other disease symptoms compared to placebo. If approved, teprotumumab has the potential to become a first-in-class treatment for TED and provide much-needed relief for patients suffering from this debilitating condition.
Another promising therapy in Horizon Therapeutics’ pipeline is KRYSTAL-1 (KRYSTEXXA Safety and Efficacy Study in Patients with Advanced Chronic Kidney Disease), a phase 3 clinical trial evaluating the safety and efficacy of Krystexxa in patients with chronic kidney disease (CKD) and uncontrolled gout. CKD is a common comorbidity in patients with gout and presents unique challenges in the management of the disease. KRYSTAL-1 aims to assess the benefits and risks of Krystexxa treatment in this patient population and provide valuable insights into the optimal management of gout in CKD.
In addition to its focus on drug development, Horizon Therapeutics is committed to expanding access to its therapies and improving healthcare outcomes for patients worldwide. The company collaborates with healthcare providers, payers, and patient advocacy organizations to raise awareness of rare and severe diseases, reduce barriers to treatment access, and support patients throughout their treatment journey. Horizon Therapeutics’ patient support programs offer financial assistance, medication access, and educational resources to help patients navigate the complexities of their condition and achieve better health outcomes.
Furthermore, Horizon Therapeutics is dedicated to corporate social responsibility and environmental sustainability. The company prioritizes ethical business practices, transparency, and accountability in all aspects of its operations. Horizon Therapeutics is committed to minimizing its environmental footprint through sustainable practices and initiatives aimed at reducing waste, conserving resources, and promoting eco-friendly alternatives. By integrating sustainability into its business strategy, Horizon Therapeutics demonstrates its commitment to making a positive impact on society and the environment.
In conclusion, Horizon Therapeutics is a leading biopharmaceutical company dedicated to improving the lives of patients with rare, autoimmune, and severe inflammatory diseases. With a patient-centric approach to drug development, a robust pipeline of innovative therapies, and a commitment to access and affordability, Horizon Therapeutics is at the forefront of advancing healthcare and transforming the treatment landscape for underserved patient populations. As the company continues to grow and innovate, it remains steadfast in its mission to deliver hope and healing to patients in need, one breakthrough therapy at a time.
